Women spend approximately 30–40% of their lives living with menopause and, by 2030, more than 1.2 billion women globally are expected to be post-menopausal.1
These figures represent one of the largest untapped commercial opportunities in preventive health, with emerging evidence placing menopause as a critical point in a woman's long-term cardiometabolic health trajectory.2
As oestrogen levels decline, women experience profound physiological changes that affect lipid metabolism, vascular function, body composition and blood pressure regulation.
Collectively, these changes contribute to a substantial increase in cardiovascular disease (CVD) risk during the menopausal life stage.3
Research shows that cardiovascular disease risk continues to rise substantially in the 10 years post-menopause.
Despite this now well-established relationship, relatively few menopause-focused nutritional products are positioned around cardiovascular or metabolic health outcomes.
Not yet a Subscriber?
This is a small extract of the full article which is available ONLY to premium content subscribers. Click below to get premium content on Nutraceutical Business Review.
Subscribe now Already a subscriber? Sign in here.
